Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

DocGo (DCGO) Research & Development (2021 - 2025)

DocGo has reported Research & Development over the past 5 years, most recently at $3.8 million for Q4 2025.

  • Quarterly results put Research & Development at $3.8 million for Q4 2025, up 2.37% from a year ago — trailing twelve months through Dec 2025 was $13.6 million (up 17.03% YoY), and the annual figure for FY2025 was $13.6 million, up 17.03%.
  • Research & Development for Q4 2025 was $3.8 million at DocGo, up from $3.2 million in the prior quarter.
  • Over the last five years, Research & Development for DCGO hit a ceiling of $3.8 million in Q4 2025 and a floor of $569351.0 in Q1 2021.
  • Median Research & Development over the past 5 years was $2.4 million (2024), compared with a mean of $2.2 million.
  • Biggest five-year swings in Research & Development: surged 135.61% in 2023 and later decreased 7.98% in 2024.
  • DocGo's Research & Development stood at $1.3 million in 2021, then rose by 28.54% to $1.7 million in 2022, then skyrocketed by 85.03% to $3.2 million in 2023, then rose by 15.7% to $3.7 million in 2024, then increased by 2.37% to $3.8 million in 2025.
  • The last three reported values for Research & Development were $3.8 million (Q4 2025), $3.2 million (Q3 2025), and $3.0 million (Q2 2025) per Business Quant data.